Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics Inc., disposed of more than $1.45 million in company stock on August 17 and 18 under a pre-arranged trading plan adopted in May.
The sales occurred under a Rule 10b5-1 plan, a mechanism designed to allow executives to transact shares at predetermined times without accusations of insider trading. Sullivan sold 37,945 shares on August 17 for between $19.16 and $20.02 each, totaling $753,333, and an additional 3,749 shares at prices between $19.70 and $20.02. On August 18, he sold 31,031 shares at prices ranging from $20.00 to $20.265, generating $697,085 from those transactions.
The sales followed option exercises on the same dates. On August 17, Sullivan acquired 37,945 shares by exercising options at $9.88 per share, spending $374,896, and an additional 2,876 shares at the same strike price. On August 18, he exercised options for 31,031 shares at $9.88, with the combined acquisition value for the latter two transactions totaling $335,001.
Avalo Therapeutics’ stock was trading at $19.74 at the time of the report. The company’s shares have delivered a 110% return over the past year, with a market capitalization of approximately $1.03 billion. The transactions were conducted under a plan adopted on May 18, 2026, with options vesting 25% on March 28, 2025 and the remainder in equal monthly increments thereafter, subject to continued service.
Recent analyst actions include coverage by Leerink, which initiated Avalo with an Outperform rating and a $38 price target, citing positive Phase 2 data for the company’s lead program abdakibart in hidradenitis suppurativa. Cantor Fitzgerald maintained an overweight rating, noting upcoming Phase 3 readouts for AbbVie’s lutikizumab in 2026. Avalo was also added to the Russell 2000 and 3000 indexes, and Ron Philip joined the board of directors.
